Marcel Nijland

2.3k total citations
92 papers, 1.1k citations indexed

About

Marcel Nijland is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Marcel Nijland has authored 92 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Pathology and Forensic Medicine, 48 papers in Oncology and 27 papers in Genetics. Recurrent topics in Marcel Nijland's work include Lymphoma Diagnosis and Treatment (75 papers), CNS Lymphoma Diagnosis and Treatment (27 papers) and CAR-T cell therapy research (22 papers). Marcel Nijland is often cited by papers focused on Lymphoma Diagnosis and Treatment (75 papers), CNS Lymphoma Diagnosis and Treatment (27 papers) and CAR-T cell therapy research (22 papers). Marcel Nijland collaborates with scholars based in Netherlands, United States and Belgium. Marcel Nijland's co-authors include Arjan Diepstra, Anke van den Berg, Josée M. Zijlstra, Lydia Visser, Tom van Meerten, Jeanette K. Doorduijn, Gustaaf W. van Imhoff, Daphne de Jong, Marie José Kersten and Philip M. Kluin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Marcel Nijland

81 papers receiving 1.0k citations

Peers

Countries citing papers authored by Marcel Nijland

Since Specialization

Citations

This map shows the geographic impact of Marcel Nijland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcel Nijland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcel Nijland more than expected).

Fields of papers citing papers by Marcel Nijland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcel Nijland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcel Nijland. The network helps show where Marcel Nijland may publish in the future.

Co-authorship network of co-authors of Marcel Nijland

This figure shows the co-authorship network connecting the top 25 collaborators of Marcel Nijland. A scholar is included among the top collaborators of Marcel Nijland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcel Nijland. Marcel Nijland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics 2025 ·Annals of Hematology ·(unknown), (unknown), Yujie Zhong, (unknown), Martijn Terpstra, (unknown), Marcel Nijland, Joost Kluiver, Arjan Diepstra, Anke van den Berg, Wouter J. Plattel	1
2	Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). 2024 ·Journal of Clinical Oncology ·Yasmin Karimi, Pau Abrisqueta, Sven de Vos, Marcel Nijland, Fritz Offner, (unknown), (unknown), (unknown), (unknown), Raúl Córdoba, Lorenzo Falchi	7
3	IBCL-278 Epcoritamab With Rituximab + Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance Therapy in FL: EPCORE NHL-2 Arms 6 and 7 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Lorenzo Falchi, Joost S.P. Vermaat, Gerardo Musuraca, Marcel Nijland, Jacob Haaber Christensen, Fritz Offner, Lori A. Leslie, Joshua Brody, Daniela Hoehn, (unknown), Liwei Wang, Jian Mei, David Belada, Pau Abrisqueta	1
4	Population Pharmacokinetic and Toxicity Analysis of High-Dose Methotrexate in Patients with Central Nervous System Lymphoma 2024 ·Clinical Pharmacokinetics ·(unknown), (unknown), Henk‐Jan Guchelaar, Marcel Nijland, Jeanette K. Doorduijn, Daan J. Touw, Thijs H. Oude Munnink, Brenda C. M. de Winter, Lena E. Friberg, Joost S.P. Vermaat, Dirk Jan A. R. Moes	3
5	Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry 2024 ·Blood Advances ·Mirian Brink, (unknown), (unknown), Marjolein van der Poel, Marie José Kersten, Mariëlle J. Wondergem, Lara H. Böhmer, Feng Jung Sherida H. Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M. Jansen, Arjan Diepstra, (unknown), Gerwin Huls, Joost S.P. Vermaat, Wouter J. Plattel, Marcel Nijland	7
6	ABCL-272 Epcoritamab + R-DHAX/C Induces Deep, Durable Responses in Transplant-Eligible Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Including High-Risk Disease 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Pau Abrisqueta, Lorenzo Falchi, Marcel Nijland, Sven de Vos, Fritz Offner, (unknown), (unknown), (unknown), (unknown), Yasmin Karimi, Raúl Córdoba	1
7	Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS 2024 ·Blood Advances ·(unknown), Carolien Duetz, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Marcel Nijland, Marjolein van der Poel, Koen de Heer, Clara Klerk, (unknown), (unknown), Rinske Boersma, Harry R. Koene, Margaretha G.M. Roemer, Erik van Werkhoven, Martine E.D. Chamuleau, Tuna Mutis	2
8	Enteropathy‐associated T‐cell lymphoma: A population‐based cohort study on incidence, treatment, and outcome in the Netherlands 2024 ·SHILAP Revista de lepidopterología ·(unknown), Mirian Brink, Wouter J. Plattel, Joost S.P. Vermaat, Marie José Kersten, Mariëlle J. Wondergem, Otto Visser, Marjolein van der Poel, Rimke Oostvogels, Feng Jung Sherida H. Woei-A-Jin, Lara H. Böhmer, (unknown), Gerwin Huls, Marcel Nijland	0
9	Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands 2023 ·Haematologica ·(unknown), Mirian Brink, Wouter J. Plattel, Marjolein van der Poel, Marie José Kersten, Mariëlle J. Wondergem, Lara H. Böhmer, Feng Jung Sherida H. Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M. Jansen, Karen J. Neelis, Anne P.G. Crijns, Laurien Daniëls, (unknown), Joost S.P. Vermaat, Gerwin Huls, Marcel Nijland	5
10	FDG-PET/CT discriminates between patients with and without lymphomas in primary Sjögren’s syndrome 2023 ·Lara D. Veeken ·(unknown), Suzanne Arends, Bert van der Vegt, Marcel Nijland, Fred K. L. Spijkervet, Arjan Vissink, Frans G. M. Kroese, Andor W.J.M. Glaudemans, Hendrika Bootsma	6
11	Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study 2023 ·Neuro-Oncology ·Jacoline E. C. Bromberg, Samar Issa, Bronno van der Holt, Matthijs van der Meulen, Linda Dirven, Monique C. Minnema, Tatjana Seute, Marc Durian, Gavin Cull, Marjolein van der Poel, Wendy B.C. Stevens, Josée M. Zijlstra, Dieta Brandsma, Marcel Nijland, Kylie D. Mason, Aart Beeker, (unknown), Martin J. van den Bent, Daphne de Jong, Jeanette K. Doorduijn	5
12	Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma 2022 ·Cancers ·Jéssica Rodrigues Plaça, Arjan Diepstra, G. Tjitske Los-de Vries, (unknown), (unknown), Pieternella J. Lugtenburg, Josée M. Zijlstra, King H. Lam, Wilson A. Silva, Bauke Ylstra, Daphne de Jong, Anke van den Berg, Marcel Nijland	1
13	Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome 2022 ·Cancers ·(unknown), Jéssica Rodrigues Plaça, Erlin A. Haacke, Martijn Terpstra, Gwenny M. Verstappen, Fred K. L. Spijkervet, Frans G. M. Kroese, Wouter J. Plattel, Joost S.P. Vermaat, Hendrika Bootsma, Bert van der Vegt, Arjan Diepstra, Anke van den Berg, Klaas Kok, Marcel Nijland	9
14	Radiotherapy Is an Excellent Bridging Strategy in Large B-Cell Lymphoma Patients Selected for CAR T-Cell Therapy 2021 ·Blood ·(unknown), Jaap A. van Doesum, Max Beijert, Marcel Nijland, Johannes A. Langendijk, Dianne M. Busz, (unknown), Gerwin Huls, Tom van Meerten	3
15	Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study 2021 ·Blood Advances ·Mirian Brink, (unknown), Joost S.P. Vermaat, Josée M. Zijlstra, Martine E.D. Chamuleau, Marie José Kersten, (unknown), Wouter J. Plattel, Pieternella J. Lugtenburg, Wendy B.C. Stevens, Rogier Mous, Elisabeth G.E. de Vries, Marjolein van der Poel, (unknown), Gerwin Huls, Tom van Meerten, Marcel Nijland	16
16	CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL 2019 ·Cancer Immunology Research ·(unknown), Yuan He, (unknown), (unknown), Ewa Cendrowicz, Rudolf S.N. Fehrmann, Emanuele Ammatuna, Christine zu Eulenburg, Marcel Nijland, Gerwin Huls, Edwin Bremer, Tom van Meerten	28
17	MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis 2019 ·Haematologica ·Joost S.P. Vermaat, (unknown), Liesbeth C. de Wreede, Willem Kraan, Ruben A. L. de Groen, Anne M.R. Schrader, Emile D. Kerver, Cornelis G. Scheepstra, Henriette W Berenschot, Wendy Deenik, Jurgen Wegman, (unknown), (unknown), Marcel Nijland, Tom van Wezel, Hendrik Veelken, Marcel Spaargaren, Arjen H.G. Cleven, Marie José Kersten, Steven T. Pals	57
18	High Prevalence of Oncogenic MYD88 and CD79B Mutations in Intravascular Large B-Cell Lymphoma: Implication for Therapy with Bruton's Kinase Inhibitors? 2017 ·Blood ·(unknown), Patty M. Jansen, Hendrik Veelken, Maarten H. Vermeer, Willem Kraan, (unknown), (unknown), Marcel Nijland, Arjan Diepstra, Marie José Kersten, Steven T. Pals, Arjen H.G. Cleven, Joost S.P. Vermaat	1
19	First Report on a Successful Screening Program for MYC Rearrangements and a Prospective Clinical Trial Based on MYC Rearrangement in Newly Diagnosed DLBCL Patients in the Netherlands 2017 ·Blood ·Martine E.D. Chamuleau, Marcel Nijland, (unknown), Nathalie J. Hijmering, Dana Chiţu, Josée M. Zijlstra, Otto Visser, Josephine M. I. Vos, Henriette W Berenschot, Rinske Boersma, Marie José Kersten, Daphne de Jong	0
20	Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens 2017 ·Annals of Hematology ·Liesbeth E.M. Oosten, Martine E.D. Chamuleau, Frederick W. Thielen, (unknown), Claire Siemes, Jeanette K. Doorduijn, (unknown), Marie José Kersten, (unknown), Joke W. Baars, (unknown), Wendy B.C. Stevens, Marcel Nijland, Gustaaf W. van Imhoff, Rolf E. Brouwer, Carin A. Uyl‐de Groot, P. M. Kluin, Daphne de Jong, Hendrik Veelken	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact